Good Friday’s US Jobs Report Surprise: 82k New Healthcare Jobs Give the Economy a Second Opinion -( $FIGS $QQQ $SPY $DIA ) by John F. Heerdink, Jr. 1 day ago Read more Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI ) by John F. Heerdink, Jr. 3 days ago Read more Register Now: Tribe Public’s 30-Minute Deep Dive on Making EoE a Once‑a‑Year Appointment -( $EPRX $SNY $IBB $XBI ) by John F. Heerdink, Jr. 4 days ago Read more When Half-Lives Matter More Than Deadlines: Inside NAYA’s Radiopharma Supply Chain- ( $IBB $XBI ) by John F. Heerdink, Jr. March 30, 2026 Read more GLOW2 Glows Brighter: Kodiak’s Diabetic Retinopathy Data and a Stock That Can Finally See Straight -( $KOD $MODD $PODD $IBB $XBI ) by John F. Heerdink, Jr. March 26, 2026 Read more Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI ) by John F. Heerdink, Jr. March 25, 2026 Read more From Lab Bench to Stockpile Shelf: GeoVax’s GEO-MVA Aims for the Big Leagues -( $GOVX $IBB $XBI ) by John F. Heerdink, Jr. March 25, 2026 Read more Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI ) by John F. Heerdink, Jr. March 25, 2026 Read more Serina Therapeutics Secures 30 Million Reasons Wall Street Is Warming to Parkinson’s Innovation -( $SER $IBB $XBI ) by John F. Heerdink, Jr. March 18, 2026 Read more Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI ) by John F. Heerdink, Jr. March 18, 2026 Read more Read more
